Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Cybin Inc. - Common Stock (NQ:HELP)

8.530 +0.630 (+7.97%)

Streaming Delayed Price Updated: 4:00 PM EST, Mar 4, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	627,717
Open	7.900
Bid (Size)	8.370 (100)
Ask (Size)	8.600 (2,800)
Prev. Close	7.900
Today's Range	7.831 - 8.550
52wk Range	5.760 - 8.970
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

TinyGemsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Dr. Freda Lewis-Hall to Board and Scientific Advisory Committee Chair

February 24, 2026

Via Investor Brand Network

Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity

February 24, 2026

EQNX::TICKER_START (NASDAQ:HELP),(CBOE:HELP),(NYSE:TAK),(NASDAQ:CMPS),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Performance

YTD	+10.3%	+10.3%
1 Month	+24.2%	+24.2%
3 Month	+10.3%	+10.3%
6 Month	+10.3%	+10.3%
1 Year	+10.3%	+10.3%

More News

Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

February 24, 2026

Via FinancialNewsMedia

Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

February 24, 2026

From Helus Pharma

Via GlobeNewswire

Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise ↗

February 20, 2026

Via MarketBeat

HELP Stock Rallies After Experimental Depression Drug Reduces Symptoms In Study: Retail Thinks Its ‘Time To Buy More’ ↗

February 17, 2026

Via Stocktwits

PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Positive Phase 2a SPL026 Data Published in Nature Medicine

February 17, 2026

Via Investor Brand Network

Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder

February 17, 2026

From Helus Pharma

Via GlobeNewswire

BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Q3 2025 Results, Advances Phase 3 and Phase 2 Programs

February 13, 2026

Via Investor Brand Network

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

February 13, 2026

From Helus Pharma

Via GlobeNewswire

BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Michael Cola as Chief Executive Officer

February 10, 2026

Via Investor Brand Network

Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

February 10, 2026

Via FinancialNewsMedia

Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution

February 10, 2026

Via FinancialNewsMedia

Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution

February 10, 2026

From Helus Pharma

Via GlobeNewswire

Frequently Asked Questions

Is Cybin Inc. - Common Stock publicly traded?

Yes, Cybin Inc. - Common Stock is publicly traded.

What exchange does Cybin Inc. - Common Stock trade on?

Cybin Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Cybin Inc. - Common Stock?

The ticker symbol for Cybin Inc. - Common Stock is HELP on the Nasdaq Stock Market

What is the current price of Cybin Inc. - Common Stock?

The current price of Cybin Inc. - Common Stock is 8.530

When was Cybin Inc. - Common Stock last traded?

The last trade of Cybin Inc. - Common Stock was at 03/04/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.